-
A total of 1,857 patients (male 768, 41.4%) were enrolled in this study. Mean age of the patients was 61.5 ± 8.7 years and mean DM duration was 7.6 ± 5.9 years. Mean SBP, DBP, and IOP were 147.39 ± 23.32 mmHg, 77.35 ± 11.36 mmHg, and 15.6 ± 3.4 mmHg, respectively. Male patients had lower SBP (146.14 ± 21.70 vs. 148.27 ± 24.37 mmHg, P = 0.048) and higher DBP (79.28 ± 11.63 vs. 75.99 ± 10.96 mmHg, P < 0.001) relative to their female counterparts. There was no significant difference in IOP between males and females (15.5 ± 3.4 vs. 15.8 ± 3.5 mmHg, P = 0.06). A total of 61.9% of patients had mean SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, while 6.4% patients had an IOP ≥ 21 mmHg. Table 1 shows the characteristics of patients with or without DR by sex.
Table 1. Characteristics of patients with or without diabetic retinopathy by sex
Item Overall Men Women No DR
(n = 1,151)DR
(n = 706)P No DR
(n = 491)DR
(n = 277)P No DR
(n = 660)DR
(n = 429)P Age 61.7 ± 8.7 61.1 ± 8.6 0.16 61.2 ± 9.4 59.6 ± 8.4 0.01 62.0 ± 8.2 62.1 ± 8.5 0.91 Male, n (%) 491 (42.7) 277 (39.2) 0.15 − − − − Duration of diabetes (years) 5.7 ± 4.8 10.6 ± 6.2 < 0.001 5.2 ± 4.6 10.5 ± 6.2 < 0.001 6.1 ± 4.9 10.6 ± 6.2 < 0.001 FPG (mmol/L) 8.7 ± 2.9 10.4 ± 3.9 < 0.001 8.9 ± 2.9 10.7 ± 4.0 < 0.001 8.6 ± 2.9 10.3 ± 3.9 < 0.001 HbA1c (%) 7.4 ± 1.9 8.3 ± 2.1 < 0.001 7.4 ± 1.9 8.5 ± 2.2 < 0.001 7.4 ± 1.8 8.2 ± 2.1 < 0.001 BMI (kg/m2) 26.49 ± 3.43 26.23 ± 3.42 0.11 26.44 ± 3.14 25.99 ± 2.96 0.051 26.52 ± 3.63 26.38 ± 3.68 0.054 SBP (mmHg) 144.47 ± 22.80 152.15 ± 23.39 < 0.001 143.71 ± 21.27 150.45 ± 21.82 < 0.001 145.04 ± 23.88 153.25 ± 24.30 < 0.001 DBP (mmHg) 77.08 ± 10.92 77.80 ± 12.03 0.19 78.95 ± 11.06 79.87 ± 12.58 0.31 75.69 ± 10.62 76.46 ± 11.48 0.25 High BP, n (%) 654 (56.8) 496 (70.2) < 0.001 289 (58.9) 191 (69.0) 0.006 365 (55.3) 305 (71.1) < 0.001 MAP 99.54 ± 12.96 102.58 ± 13.84 < 0.001 100.53 ± 12.64 103.40 ± 13.78 0.004 98.80 ± 13.15 102.06 ± 13.87 < 0.001 IOP 15.63 ± 3.59 15.66 ± 3.16 0.86 15.49 ± 3.53 15.42 ± 3.06 0.79 15.74 ± 3.64 15.81 ± 3.22 0.73 High IOP, n (%) 84 (7.3) 34 (4.8) 0.03 37 (7.5) 10 (3.6) 0.03 47 (7.1) 24 (5.6) 0.32 MOPP 50.73 ± 8.43 52.73 ± 9.15 < 0.001 51.54 ± 8.38 53.51 ± 9.25 0.003 50.13 ± 8.43 52.23 ± 9.07 < 0.001 Note. FPG: fasting plasma glucose; HbA1c: glycosylated hemoglobin A1c; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; IOP: intraocular pressure; MOPP: mean ocular perfusion pressure; DR: diabetic retinopathy. High BP is defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg; high IOP is defined as IOP ≥ 21 mmHg. Table 2 shows the mean MOPP value for male, female, and combined male and female patients. Mean MOPP for all patients was 51.49 ± 8.77 mmHg. Male patients had a higher MOPP than female patients (52.25 ± 8.75 vs. 50.96 ± 8.74 mmHg, P = 0.002). Both male and female patients (and combined male and female patients) with any type of DR or NPDR had significantly higher MOPP values than patients without DR. Male patients (and combined male and female patients) with ME also had significantly higher MOPP values than did patients without ME.
Table 2. MOPP values by sex in the study population
Item Overall Male Female n Mean ± SD P n Mean ± SD P n Mean ± SD P Overall 1,857 51.49 ± 8.77 − 768 52.25 ± 8.75 − 1,089 50.96 ± 8.74 − Retinopathy No DR 1,151 50.73 ± 8.43 Ref 491 51.54 ± 8.38 Ref 660 50.13 ± 8.43 Ref Any DR 706 52.73 ± 9.15 < 0.001 277 53.51 ± 9.25 0.003 429 52.23 ± 9.07 < 0.001 NPDR 639 52.74 ± 9.23 Sig 251 53.32 ± 9.30 Sig 388 52.37 ± 9.18 Sig PDR 67 52.62 ± 8.40 NS 26 55.33 ± 8.71 NS 41 50.89 ± 7.82 NS Non-STDR 516 52.72 ± 9.44 Sig 205 53.19 ± 9.68 NS 311 52.40 ± 9.28 Sig STDR 190 52.76 ± 8.34 Sig 72 54.41 ± 7.88 Sig 118 51.76 ± 8.48 NS Maculopathy No ME 1,548 51.17 ± 8.64 Ref 656 51.86 ± 8.72 Ref 892 50.67 ± 8.56 Ref ME 250 53.01 ± 9.26 0.002 89 54.78 ± 8.75 0.003 161 52.03 ± 9.41 0.070 Non-CSME 120 53.58 ± 10.08 Sig 42 55.80 ± 9.35 Sig 78 52.39 ± 10.31 NS CSME 130 52.47 ± 8.43 NS 47 53.87 ± 8.17 NS 83 51.69 ± 8.52 NS Note. MOPP: mean ocular perfusion pressure; DR: diabetic retinopathy; NPDR: non-proliferative DR; PDR: proliferative DR; STDR: sight-threatening DR; ME: macular edema; CSME: clinically significant ME; SD: standard deviation; Ref: reference group; Sig: significant; NS: not significant. Table 3 shows the multivariate linear regression results for the factors associated with MOPP. Table 4 shows the association between DR prevalence and the risk factors. In a stepwise multivariate regression model, we found that sex, FPG, BMI, serum creatinine, LDL, HDL, and urine protein levels were significantly associated with MOPP. Furthermore, WHR and blood urea nitrogen were almost significantly associated with MOPP (Table 3). We also found that MOPP, age, refractive error, income level, DM duration, FPG, HbA1c, TG, and urine protein levels were significantly associated with DR after adjusting for MOPP and similar risk factors in a multivariate logistical model. Furthermore, TC was almost significantly associated with DR (Table 4).
Table 3. Factors associated with MOPP in the study population
Factors β coefficient 95% CI Standardized β coefficient P value VIF Sex (male, female) −0.90 −1.78, −0.03 −0.05 0.04 1.23 Fasting plasma glucose (mmol/L) 0.13 0.02, 0.25 0.05 0.03 1.04 Body mass index (kg/m2) 0.40 0.28, 0.51 0.15 < 0.001 1.05 Waist/hip ratio 5.91 −0.20, 12.02 0.04 0.06 1.04 Serum creatinine (μmmol/L) 0.03 0.01, 0.06 0.08 0.002 1.21 Blood urea nitrogen (mmol/L) −0.12 −0.24, 0.01 −0.04 0.06 1.06 Low-density lipoprotein (mmol/L) 0.58 0.15, 1.00 0.06 0.01 1.07 High-density lipoprotein (mmol/L) −1.26 −2.34, −0.17 −0.05 0.02 1.09 Urine protein level (5 levels) 0.71 0.43, 0.99 0.11 < 0.001 1.03 Note. CI: confidence interval; MOPP: mean ocular perfusion pressure; VIF: variance inflation factor. Table 4. PLEASE SEE the table of the supplement word file in reply email, since it was changed much
Risk factors OR (95% CI) P value MOPP (mmHg) 1.03 (1.02, 1.04) < 0.001 Age (years) 0.98 (0.97, 0.99) 0.002 Refractive error (diopter) 1.07 (1.02, 1.11) 0.002 Income level (3 levels) 0.76 (0.62, 0.92) 0.006 Duration of DM (years) 1.17 (1.15, 1.20) < 0.001 Fasting plasma glucose (mmol/L) 1.07 (1.02, 1.11) 0.003 HbA1c (%) 1.12 (1.05, 1.20) 0.001 Total cholesterol (mmol/L) 1.09 (1.00, 1.20) 0.056 Total triglycerides (mmol/L) 0.90 (0.84, 0.97) 0.005 Urine protein level (5 levels) 1.17 (1.08, 1.26) < 0.001 Note. OR: odds ratio; CI: confidence interval; MOPP: mean ocular perfusion pressure; DM: diabetes mellitus; HbA1c: glycosylated hemoglobin A1c. In further logistic analyses, after adjusting for factors remaining in the previous multivariate regression model, we found that increased MOPP (per 1 mmHg) was significantly associated with the presence of any type of DR [odds (OR) = 1.03, 95% confidence interval (CI): 1.02–1.04, P < 0.001], NPDR (OR = 1.03, 95% CI: 1.02–1.04, P < 0.001), and non-STDR (OR = 1.03, 95% CI: 1.01–1.04, P < 0.001). Moreover, increased MOPP (per 1 mmHg) was found to be associated with increased ME likelihood (OR = 1.02, 95% CI: 1.01–1.04, P = 0.008). However, no significant association was found between MOPP and PDR, non-STDR and STDR, or non-CSME and CSME (Table 5) relative to NPDR.
Table 5. Multivariate logistic regression analysis of MOPP (per 1 mmHg) for the prevalence/severity of DR and ME
Item OR (95% CI) P value No DR vs. Any DR 1.03 (1.02, 1.04) < 0.001 No DR vs. NPDR 1.03 (1.02, 1.04) < 0.001 NPDR vs. PDR 0.99 (0.96, 1.03) 0.660 No DR vs. non-STDR 1.03 (1.01, 1.04) < 0.001 non-STDR vs. STDR 1.00 (0.98, 1.02) 0.750 No ME vs. ME 1.02 (1.01, 1.04) 0.008 Non-CSME vs. CSME 0.99 (0.96, 1.02) 0.350 Note. MOPP: mean ocular perfusion pressure; DR: diabetic retinopathy; ME: macular edema; NPDR: non-proliferative DR; PDR: proliferative DR; CSME: clinically significant ME; OR: odds ratio; CI: confidence interval; STDR: sight-threatening DR. The multivariate logistic regression models adjusted for MOPP, age, refractive error, income level, duration of diabetes mellitus, fasting blood glucose, HbA1c, total cholesterol, total triglycerides, and urine protein level.
doi: 10.3967/bes2020.091
Association between Mean Ocular Perfusion Pressure and Diabetic Retinopathy in a Northeastern Chinese Population
-
Abstract:
Objective To evaluate the association between diabetic retinopathy (DR) and mean ocular perfusion pressure (MOPP) in patients with type 2 diabetes mellitus (T2DM). Methods Patients from the Fushun Diabetic Retinopathy Cohort Study (FS-DIRECT), a community-based prospective cohort study conducted in northeast China, were included in this study. The presence and severity of DR were determined by grading fundus photographs according to the Early Treatment Diabetic Retinopathy Study (ETDRS) retinopathy scale. Systolic and diastolic blood pressure (SBP and DBP) were recorded using an electronic sphygmomanometer. Intraocular pressure (IOP) was measured using an iCare rebound tonometer. MOPP was calculated using the formula MOPP = 2/3 [DBP + 1/3 (SBP − DBP)] − IOP. Results In total, 1,857 patients who had gradable fundus photography and MOPP data were enrolled in this study. Male patients had a higher MOPP than female patients (52.25 ± 8.75 vs. 50.96 ± 8.74 mmHg, P = 0.002). Overall, both male and female patients with any type of DR, non-proliferative DR (NPDR), or non-sight-threatening DR (non-STDR) had significantly higher MOPP relative to patients without DR. Increased MOPP (per 1 mmHg) was in turn associated with the presence of any type of DR [odds ratio (OR) = 1.03, 95% confidence interval (CI) : 1.02–1.04], NPDR (OR = 1.03 95% CI: 1.02–1.04), and non-STDR (OR = 1.03, 95% CI: 1.01–1.04) after adjusting for confounders. Increased MOPP (per 1 mmHg) was also associated with an increased likelihood of macular edema (OR = 1.02 , 95% CI: 1.01–1.04). Conclusions The results suggest that increased MOPP was associated with DR and macular edema in northeastern Chinese patients with T2DM. -
Table 1. Characteristics of patients with or without diabetic retinopathy by sex
Item Overall Men Women No DR
(n = 1,151)DR
(n = 706)P No DR
(n = 491)DR
(n = 277)P No DR
(n = 660)DR
(n = 429)P Age 61.7 ± 8.7 61.1 ± 8.6 0.16 61.2 ± 9.4 59.6 ± 8.4 0.01 62.0 ± 8.2 62.1 ± 8.5 0.91 Male, n (%) 491 (42.7) 277 (39.2) 0.15 − − − − Duration of diabetes (years) 5.7 ± 4.8 10.6 ± 6.2 < 0.001 5.2 ± 4.6 10.5 ± 6.2 < 0.001 6.1 ± 4.9 10.6 ± 6.2 < 0.001 FPG (mmol/L) 8.7 ± 2.9 10.4 ± 3.9 < 0.001 8.9 ± 2.9 10.7 ± 4.0 < 0.001 8.6 ± 2.9 10.3 ± 3.9 < 0.001 HbA1c (%) 7.4 ± 1.9 8.3 ± 2.1 < 0.001 7.4 ± 1.9 8.5 ± 2.2 < 0.001 7.4 ± 1.8 8.2 ± 2.1 < 0.001 BMI (kg/m2) 26.49 ± 3.43 26.23 ± 3.42 0.11 26.44 ± 3.14 25.99 ± 2.96 0.051 26.52 ± 3.63 26.38 ± 3.68 0.054 SBP (mmHg) 144.47 ± 22.80 152.15 ± 23.39 < 0.001 143.71 ± 21.27 150.45 ± 21.82 < 0.001 145.04 ± 23.88 153.25 ± 24.30 < 0.001 DBP (mmHg) 77.08 ± 10.92 77.80 ± 12.03 0.19 78.95 ± 11.06 79.87 ± 12.58 0.31 75.69 ± 10.62 76.46 ± 11.48 0.25 High BP, n (%) 654 (56.8) 496 (70.2) < 0.001 289 (58.9) 191 (69.0) 0.006 365 (55.3) 305 (71.1) < 0.001 MAP 99.54 ± 12.96 102.58 ± 13.84 < 0.001 100.53 ± 12.64 103.40 ± 13.78 0.004 98.80 ± 13.15 102.06 ± 13.87 < 0.001 IOP 15.63 ± 3.59 15.66 ± 3.16 0.86 15.49 ± 3.53 15.42 ± 3.06 0.79 15.74 ± 3.64 15.81 ± 3.22 0.73 High IOP, n (%) 84 (7.3) 34 (4.8) 0.03 37 (7.5) 10 (3.6) 0.03 47 (7.1) 24 (5.6) 0.32 MOPP 50.73 ± 8.43 52.73 ± 9.15 < 0.001 51.54 ± 8.38 53.51 ± 9.25 0.003 50.13 ± 8.43 52.23 ± 9.07 < 0.001 Note. FPG: fasting plasma glucose; HbA1c: glycosylated hemoglobin A1c; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; IOP: intraocular pressure; MOPP: mean ocular perfusion pressure; DR: diabetic retinopathy. High BP is defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg; high IOP is defined as IOP ≥ 21 mmHg. Table 2. MOPP values by sex in the study population
Item Overall Male Female n Mean ± SD P n Mean ± SD P n Mean ± SD P Overall 1,857 51.49 ± 8.77 − 768 52.25 ± 8.75 − 1,089 50.96 ± 8.74 − Retinopathy No DR 1,151 50.73 ± 8.43 Ref 491 51.54 ± 8.38 Ref 660 50.13 ± 8.43 Ref Any DR 706 52.73 ± 9.15 < 0.001 277 53.51 ± 9.25 0.003 429 52.23 ± 9.07 < 0.001 NPDR 639 52.74 ± 9.23 Sig 251 53.32 ± 9.30 Sig 388 52.37 ± 9.18 Sig PDR 67 52.62 ± 8.40 NS 26 55.33 ± 8.71 NS 41 50.89 ± 7.82 NS Non-STDR 516 52.72 ± 9.44 Sig 205 53.19 ± 9.68 NS 311 52.40 ± 9.28 Sig STDR 190 52.76 ± 8.34 Sig 72 54.41 ± 7.88 Sig 118 51.76 ± 8.48 NS Maculopathy No ME 1,548 51.17 ± 8.64 Ref 656 51.86 ± 8.72 Ref 892 50.67 ± 8.56 Ref ME 250 53.01 ± 9.26 0.002 89 54.78 ± 8.75 0.003 161 52.03 ± 9.41 0.070 Non-CSME 120 53.58 ± 10.08 Sig 42 55.80 ± 9.35 Sig 78 52.39 ± 10.31 NS CSME 130 52.47 ± 8.43 NS 47 53.87 ± 8.17 NS 83 51.69 ± 8.52 NS Note. MOPP: mean ocular perfusion pressure; DR: diabetic retinopathy; NPDR: non-proliferative DR; PDR: proliferative DR; STDR: sight-threatening DR; ME: macular edema; CSME: clinically significant ME; SD: standard deviation; Ref: reference group; Sig: significant; NS: not significant. Table 3. Factors associated with MOPP in the study population
Factors β coefficient 95% CI Standardized β coefficient P value VIF Sex (male, female) −0.90 −1.78, −0.03 −0.05 0.04 1.23 Fasting plasma glucose (mmol/L) 0.13 0.02, 0.25 0.05 0.03 1.04 Body mass index (kg/m2) 0.40 0.28, 0.51 0.15 < 0.001 1.05 Waist/hip ratio 5.91 −0.20, 12.02 0.04 0.06 1.04 Serum creatinine (μmmol/L) 0.03 0.01, 0.06 0.08 0.002 1.21 Blood urea nitrogen (mmol/L) −0.12 −0.24, 0.01 −0.04 0.06 1.06 Low-density lipoprotein (mmol/L) 0.58 0.15, 1.00 0.06 0.01 1.07 High-density lipoprotein (mmol/L) −1.26 −2.34, −0.17 −0.05 0.02 1.09 Urine protein level (5 levels) 0.71 0.43, 0.99 0.11 < 0.001 1.03 Note. CI: confidence interval; MOPP: mean ocular perfusion pressure; VIF: variance inflation factor. Table 4. PLEASE SEE the table of the supplement word file in reply email, since it was changed much
Risk factors OR (95% CI) P value MOPP (mmHg) 1.03 (1.02, 1.04) < 0.001 Age (years) 0.98 (0.97, 0.99) 0.002 Refractive error (diopter) 1.07 (1.02, 1.11) 0.002 Income level (3 levels) 0.76 (0.62, 0.92) 0.006 Duration of DM (years) 1.17 (1.15, 1.20) < 0.001 Fasting plasma glucose (mmol/L) 1.07 (1.02, 1.11) 0.003 HbA1c (%) 1.12 (1.05, 1.20) 0.001 Total cholesterol (mmol/L) 1.09 (1.00, 1.20) 0.056 Total triglycerides (mmol/L) 0.90 (0.84, 0.97) 0.005 Urine protein level (5 levels) 1.17 (1.08, 1.26) < 0.001 Note. OR: odds ratio; CI: confidence interval; MOPP: mean ocular perfusion pressure; DM: diabetes mellitus; HbA1c: glycosylated hemoglobin A1c. Table 5. Multivariate logistic regression analysis of MOPP (per 1 mmHg) for the prevalence/severity of DR and ME
Item OR (95% CI) P value No DR vs. Any DR 1.03 (1.02, 1.04) < 0.001 No DR vs. NPDR 1.03 (1.02, 1.04) < 0.001 NPDR vs. PDR 0.99 (0.96, 1.03) 0.660 No DR vs. non-STDR 1.03 (1.01, 1.04) < 0.001 non-STDR vs. STDR 1.00 (0.98, 1.02) 0.750 No ME vs. ME 1.02 (1.01, 1.04) 0.008 Non-CSME vs. CSME 0.99 (0.96, 1.02) 0.350 Note. MOPP: mean ocular perfusion pressure; DR: diabetic retinopathy; ME: macular edema; NPDR: non-proliferative DR; PDR: proliferative DR; CSME: clinically significant ME; OR: odds ratio; CI: confidence interval; STDR: sight-threatening DR. The multivariate logistic regression models adjusted for MOPP, age, refractive error, income level, duration of diabetes mellitus, fasting blood glucose, HbA1c, total cholesterol, total triglycerides, and urine protein level. -
[1] Guyton AC. Textbook of medical physiology. 7th ed. Philadelphia, PA: WB Saunders Co, 1986; 393-409. [2] Quigley M, Cohen S. A new pressure attenuation index to evaluate retinal circulation. A link to protective factors in diabetic retinopathy. Arch Ophthalmol, 1999; 117, 84−9. doi: 10.1001/archopht.117.1.84 [3] Yoshida A, Feke GT, Morales-Stoppello J, et al. Retinal blood flow alterations during progression of diabetic retinopathy. Arch Ophthalmol, 1983; 101, 225−7. doi: 10.1001/archopht.1983.01040010227008 [4] Patel V, Rassam S, Newsom R, et al. Retinal blood flow in diabetic retinopathy. BMJ, 1992; 305, 678−83. doi: 10.1136/bmj.305.6855.678 [5] Dimitrova G, Kato S, Yamashita H, et al. Relation between retrobulbar circulation and progression of diabetic retinopathy. Br J Ophthalmol, 2003; 87, 622−5. doi: 10.1136/bjo.87.5.622 [6] Moss SE, Klein R, Klein BE. Ocular factors in the incidence and progression of diabetic retinopathy. Ophthalmology, 1994; 101, 77−83. doi: 10.1016/S0161-6420(94)31353-4 [7] Roy MS, Klein R. Macular edema and retinal hard exudates in African Americans with type 1 diabetes: the New Jersey 725. Arch Ophthalmol, 2001; 119, 251−9. [8] Raman R, Gupta A, Kulothungan V, et al. Association of mean ocular perfusion pressure and diabetic retinopathy in type 2 diabetes mellitus: Sankara Nethralaya diabetic retinopathy epidemiology and molecular genetic study (SN-DREAMS, Report 28). Invest Ophthalmol Vis Sci, 2011; 52, 4592−7. doi: 10.1167/iovs.10-6903 [9] Wang Y, Lin Z, Wen L, et al. Rationale, Design, Methodology and Baseline Data of Fushun Diabetic Retinopathy Cohort Study (FS-DIRECT). Ophthalmic epidemiology, 2020; 27, 73–82. [10] American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2005; 28, 37−42. doi: 10.2337/diacare.28.suppl_1.S37 [11] Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 1991; 98, 786-806. [12] Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol, 2002; 156, 871−81. doi: 10.1093/aje/kwf113 [13] Kohner EM. The effect of diabetic control on diabetic retinopathy. Eye, 1993; 7, 309−11. doi: 10.1038/eye.1993.66 [14] Zheng Y, Wong TY, Mitchell P, et al. Distribution of ocular perfusion pressure and its relationship with open-angle glaucoma: the singapore malay eye study. Invest Ophthalmol Vis Sci, 2010; 51, 3399−404. doi: 10.1167/iovs.09-4867 [15] Langham ME, Grebe R, Hopkins S, et al. Choroidal blood flow in diabetic retinopathy. Experimental eye research, 1991; 52, 167−73. doi: 10.1016/0014-4835(91)90256-E [16] Konno S, Feke GT, Yoshida A, et al. Retinal blood flow changes in type I diabetes. A long-term follow-up study. Invest Ophthalmol Vis Sci, 1996; 37, 1140−8. [17] Cuypers MH, Kasanardjo JS, Polak BC. Retinal blood flow changes in diabetic retinopathy measured with the Heidelberg scanning laser Doppler flowmeter. Graefes Arch Clin Exp Ophthalmol, 2000; 238, 935−41. doi: 10.1007/s004170000207 [18] Man RE, Sasongko MB, Xie J, et al. Decreased retinal capillary flow is not a mediator of the protective myopia-diabetic retinopathy relationship. Invest Ophthalmol Vis Sci, 2014; 55, 6901−7. doi: 10.1167/iovs.14-15137 [19] Agemy SA, Scripsema NK, Shah CM, et al. Retinal vascular perfusion density mapping using optical coherence tomography angiography in normals and diabetic retinopathy patients. Retina, 2015; 35, 2353−63. doi: 10.1097/IAE.0000000000000862 [20] Mastropasqua R, D'Aloisio R, Di Antonio L, et al. Widefield optical coherence tomography angiography in diabetic retinopathy. Acta diabetologica, 2019; 56, 1293−303. doi: 10.1007/s00592-019-01410-w [21] Ishibazawa A, De Pretto LR, Alibhai AY, et al. Retinal nonperfusion relationship to arteries or veins observed on widefield optical coherence tomography angiography in diabetic retinopathy. Invest Ophthalmol Vis Sci, 2019; 60, 4310−8. doi: 10.1167/iovs.19-26653 [22] Yang D, Cao D, Huang Z, et al. Macular capillary perfusion in chinese patients with diabetic retinopathy obtained with optical coherence tomography angiography. Ophthalmic Surg Lasers Imaging Retina, 2019; 50, e88−95. doi: 10.3928/23258160-20190401-12 [23] Tan TE, Nguyen Q, Chua J, et al. Global assessment of retinal arteriolar, venular and capillary microcirculations using fundus photographs and optical coherence tomography angiography in diabetic retinopathy. Sci Rep, 2019; 9, 11751. doi: 10.1038/s41598-019-47770-9 [24] Furino C, Montrone G, Cicinelli MV, et al. Optical coherence tomography angiography in diabetic patients without diabetic retinopathy. Eur J Ophthalmol, 2019; 1120672119895701. [25] Wong B, Parikh D, Rosen L, et al. Comparison of disposable goldmann applanation tonometer, icare ic100, and tonopen xl to standards of care goldmann nondisposable applanation tonometer for measuring intraocular pressure. J Glaucoma, 2018; 27, 1119−24. doi: 10.1097/IJG.0000000000001059